FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.24  |  FHIR Version n/a  User: [n/a]

38060511000001101: Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 19-Feb 2020. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
1243801000001119 Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
1243821000001114 Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Is a Exenatide 2mg/0.85ml prolonged-release suspension for injection pre-filled disposable devices true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Is a Bydureon true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Has dispensed dose form Prolonged-release suspension for injection true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Has specific active ingredient Exenatide true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) 4 pre-filled disposable injection Has AMP True Bydureon BCise 2mg/0.85ml prolonged-release suspension for injection pre-filled pens (AstraZeneca UK Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start